EGFR and non-small cell lung carcinoma: Synchronous oligometastatic disease may be rare, accounting for only 6% of patients with advanced EGFR-mutated NSCLC [15], while oligo-residual disease accounts for approximately 30% of EGFR-mutated NSCLC patients.